Sibert L, Planet M, Kuhn J M, Annoot M, Boillot B, Grise P
Service d'Urologie, C.H.U. de Rouen.
Prog Urol. 1994 Aug-Sep;4(4):582-7.
The authors report a case of hypothyroidism occurring during cytokine treatment of metastatic renal cancer. This is a relatively rare complication of immunotherapy, whose aetiopathogenesis remains unclear. Possible hypotheses include an autoimmune process or direct toxicity. Thyroid function tests at the start of immunotherapy and regular monitoring are therefore recommended during treatment with interferon and/or interleukin. If hypothyroidism is not recognised, its clinical symptoms and signs could be attributed to cytokine toxicity, leading to unwarranted discontinuation of treatment when L-thyroxin replacement therapy would have been sufficient.
作者报告了一例在转移性肾癌细胞因子治疗期间发生甲状腺功能减退的病例。这是免疫治疗中一种相对罕见的并发症，其发病机制尚不清楚。可能的假说是自身免疫过程或直接毒性。因此，建议在使用干扰素和/或白细胞介素治疗期间，在免疫治疗开始时进行甲状腺功能检查并定期监测。如果未识别出甲状腺功能减退，其临床症状和体征可能归因于细胞因子毒性，导致在左甲状腺素替代治疗就足够的情况下不必要地中断治疗。
